About Humacyte, Inc. Common Stock
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Market Cap
$0.26B
Employees
185
Listed Since
August 27, 2021
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Website
www.humacyte.comPhone
919-313-9633
Headquarters
2525 EAST NORTH CAROLINA HIGHWAY 54
DURHAM, NC 27713
CIK
0001818382